Abstract: The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, and their use in therapy.

Abstract: The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, and their use in therapy.

Abstract: The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, and their use in therapy.

Abstract: A method of additively manufacturing a minimal surface structure of a three-dimensional article includes a computer executing the steps of recording, in the computer, an envelope of the three-dimensional article; generating a density field across a volume enclosed by the envelope with densities of the density field corresponding to local requirement values of at least one physical parameter at respective positions of the three-dimensional article; generating an adaptive Voronoi tessellation of the volume using the density field; generating a first skeleton graph associated with the adaptive Voronoi tessellation; generating a second skeleton graph associated with the first skeleton graph; and generating a digital minimal surface model from the first and second skeleton graphs. The method may further include a 3D printer additively manufacturing the minimal surface structure according to the digital minimal surface model.

Abstract: The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, and their use in therapy.

Abstract: The invention relates to novel use of Pancreatic Polypeptides as well as novel Pancreatic Polypeptides and compositions thereof. Such peptides can be used in treating or preventing conditions responsive to Y4 and/or Y5 receptor activation, such as cachexia.

Abstract: The present invention relates to PYY derivatives comprising a serum albumin binding side chain, wherein said derivative has a half-life of at least 7 hours as determined by Assay (IV) described herein as well as compositions comprising said derivative and its use in therapy.

Abstract: The present invention relates to a PYY or PP peptide derivative or analogue thereof derivatised with one or more serum albumin binding side chains comprising a dis-tal tetrazole or carboxylic acid group. Moreover, the invention relates to compositions hereof and methods of treatment of conditions responsive to Y receptor modulation.